Bruce is Chairman and Co-founder of Nimbus Therapeutics and General Partner at Atlas Venture. He is also currently Chairman of Arkuda Therapeutics, AvroBio (NASDAQ: AVRO), Hotspot Therapeutics, Kymera Therapeutics (NASDAQ: KYMR), and Quench Bio. He also serves on the board of Magenta Therapeutics (NASDAQ: MGTA) and several seed-stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics, miRagen (NASDAQ: MGEN), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), Unum Therapeutics (NASDAQ: UMRX), and a number of other ventures. Bruce serves or has served as an advisor in various capacities to Takeda, UCB, and the Gates Foundation. He also serves on the boards of The Pennsylvania State Research Foundation, which helps with technology transfer for Penn State, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes. Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a DPhil (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Rajeev joined SR One in 2004 and is an alum of the Kauffman Fellows Program. His prior and current investments include Adheron, iPierian, True North, Propeller Health, Concert Pharmaceuticals, CyDex Pharmaceuticals, NeuroTherapeutics Pharma, Tranquis Therapeutics, IlluminOss Medical, and Avhana Health. Rajeev also spent time with GSK’s competitive excellence group, where he worked on company-wide strategic projects and operational projects. Prior to SR One, Rajeev worked at Genentech, where his role included technology and clinical development, and at Bio-Rad Laboratories in a product development role. In addition, Rajeev has worked in business development at Genome Therapeutics and was a co-founder of Unimicro Technologies. Rajeev received his BA in chemistry and mathematics from Knox College, his MBA from the Wharton School of The University of Pennsylvania and his PhD in chemistry from Stanford University.

Jean is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston, MA, office. She also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma (NASDAQ: XLRN), Calithera Biosciences (NASDAQ: CALA), Catabasis Pharmaceuticals (NASDAQ: CATB), Cyteir Therapeutics, Disarm Therapeutics, Flex Pharma (NASDAQ: FLKS), Five Prime Therapeutics (NASDAQ: FPRX), Gemini Therapeutics, Hydra Biosciences, Hypnion (acquired by Eli Lilly), Locana Therapeutics, Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapetics, Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ). Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. Prior to LSV and ATV, Jean worked for BancBoston Ventures and led its life sciences investments in Neurometrix (NASDAQ: NURO), Ironwood Pharmaceuticals (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters), and Syntonix Pharmaceuticals (acquired by Biogen/Idec). Jean has been in the biopharmaceutical industry for over 30 years. She received an MBA from Simmons College Graduate School of Management and her BS from the University of Maine.

Mark has 25 years of experience as a pharmaceutical industry leader managing all stages of drug development and commercialization in multiple therapeutic areas for several high-performance companies. Mark is the Chairman and CEO of Kala Pharmaceuticals and previously was CEO of Civitas Therapeutics which was sold to Acorda Therapeutics in 2014. Prior to joining Civitas, he was President and CEO of Blend Therapeutics, a nanotechnology oncology biotech company. He also served as President and CEO of Sunovion Pharmaceuticals, where he provided leadership for the successful launch of that company, which was created following the acquisition of Sepracor by Sumitomo Dainippon Pharmaceuticals. Mark also previously held key senior leadership roles with Sepracor and Novartis Pharmaceuticals. He currently also sits on the board of directors for Kala Pharmaceuticals, Allergen Research Corporation, and Taris Biomedical.

Jeb has served Nimbus as President and Chief Executive Officer and as a member of the board of directors since October 2018. He previously served as Chief Business Officer from November 2014 to October 2018 and as Chief Financial Officer from February 2017 to October 2018. Since joining Nimbus, Jeb has overseen the discovery and development of three programs into clinical testing across a range of indications, over $400M raised in equity funding, executed deals worth over $7B, and the return of over $4B in gains back to equity holders. Prior to joining Nimbus, Jeb served as the Vice President of Business Development at GSK Oncology (a subsidiary of GlaxoSmithKline plc [NYSE: GSK]) from March 2011 to October 2014, where he was responsible for identifying and concluding several critical collaborations for GSK in oncology, including the Novartis-GSK oncology integration, and spent a decade at GSK in various business development leadership roles. Prior to GSK, Jeb was a consultant at McKinsey & Company starting in September 2000–2002, then September 2004–2005, after having started his career as a pharmaceutical chemist at Pfizer Inc. (NYSE: PFE) in 1998. Jeb currently serves as a member of the board of directors at private biotechnology companies Cardurion Pharmaceuticals, Inc. and ROME Therapeutics, Inc. Jeb received bachelor’s degrees in chemistry and chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management with joint program in biomedical enterprises with the Harvard Medical School.

Katharine has more than 20 years of experience in the pharmaceutical industry including global clinical research, medical affairs, and patient safety across both big pharma and smaller biotechnology companies. She has strategically led multiple research and development efforts that have resulted in regulatory approvals and launches of several commercial therapies. She is currently a board member at Marker Therapeutics, Inc. (NASDAQ: MRKR) and Pliant Therapeutics, Inc. (NASDAQ: PLRX). She most recently served as Chief Medical Officer of Agilent Technologies. Previously, Kate was Chief Medical Officer and Head of Research and Development at Kaleido Biosciences. She also spent more than 20 years at GlaxoSmithKline (GSK) in roles of increasing responsibility, most recently serving as Chief Medical Officer. In this role, she led medical governance across the pharmaceutical, vaccines, and consumer business units. She also directed development of multiple new chemical entities and product line extensions and established the GSK clinical development organization in China. During her career, Kate led the strategic development and delivery of presentations before regulatory agencies worldwide including nine FDA Advisory Committee meetings. She earned her BA in biology from Cornell University and her MD from the University of Texas Southwestern Medical School.

Anne currently serves as Operating Partner at Havencrest Healthcare Partners and on the faculty of University of North Carolina’s School of Public Health. She has more than 35 years of experience advising healthcare and life sciences businesses in areas of financial and strategic growth. Anne also established and served as Managing Partner of Grant Thornton’s Global Health Care and Life Sciences Practices for more than a decade, and prior to that was a partner with both Deloitte and Arthur Andersen. She serves as board member and Audit Committee Chair for Magenta Therapeutics, SOC Telemed, and CitiusTech, and as Board Chair for Be The Match Foundation. Anne holds a BBA in business administration and accounting from The College of William & Mary and an MS in accounting from the University of Virginia.

Laura is a Principal on the investment team at RA Capital Management. Laura works on both public and private investments and serves as a board director for Artiva Biotherapeutics and Acumen Pharmaceuticals and as a board observer for Vor Biopharma. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Laura holds a BA in biology and psychology from Harvard University, and a PhD in neuroscience from MIT. Her graduate research investigated synaptic translation in syndromic autism.

George is a scientifically trained executive with nearly 40 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. George was previously President, CEO, and CSO of Navitor Pharmaceuticals, Inc., and currently serves as a board member and consultant. George also serves on the boards of Nimbus Therapeutics and Riparian Pharmaceuticals as well as a consultant and scientific advisor to several biopharmaceutical companies. Before joining Navitor, George served as CEO of Sirtris, a GlaxoSmithKline Company. Prior to Sirtris, George was Vice President, Metabolic Disease and Hemophilia Research, at Wyeth Pharmaceuticals. George also previously served as Chief Scientific Officer and Executive Vice President of Research and Development at Corvas International, prior to the merger of Corvas and Dendreon Corporation. Earlier in his career, George led a research team at Merck and Co., and was responsible for multiple discovery programs in the field of cardiovascular medicine. George is the author of more than 100 peer-reviewed scientific publications, book chapters, and reviews, and 38 issued US and foreign patents.